Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I tend to align to this timeframe as well. Either way not long. Three weeks max
My mind just got blown. VERY INTERESTING
No, they wanted a completed trial. It is a double blind study and I blinding it compromises data integrity in addition to compromising ongoing treatments. You two need to read up on clinical trial structure, regulations, and data. You sending misleading and misinformed (borderline idiotic) messages helps no one here to understand what is going on. The fact FDA wants the trial to be completed is a big deal! Not the other way around...
No. In this case, getting shot down would mean trial failure...and did that happen??
So then saying continue the trial meant they didn’t get the EUA yet???? NO SHIT SHERLOCK! FDA simply wants a full data set with all patients through their primary endpoint at 28 days. Simple as that! This is a small trial size, and even though already historically proven quite safe, if you’re going to grant EUA you want statistically relevant data. You cut a trial short then you leave risk that endpoint is missed in a trial with such a small number of participants. Honestly this is all logical and is the proper procedure for scientific studies or research in clinical settings. So please, stop with your nonsense.
No. That has zero truth to it. They added more people to their DMC to ensure when they meet full enrollment the data and recommendations by the DMC do not get slighted by any agency. Pretty easy to see your angle here.
What therapeutic company hasn’t been snubbed??? There isn’t a single one that has been support or even mentioned by OWS or US leaders. Meanwhile, Javitt likely knew (IMO) that being on the board would represent a conflict of interest with any merger NRX would go through. Why they announced what they did is a mystery but it is not all that surprising
I honestly do not know, I was just putting my thoughts out there. Might have been over for a while now. I think it is about 5pm there, so I would think if it is not done yet it will be very soon
Would love to see an update from leadership after the meeting concludes
Interesting finish! Haven’t seen that happen here in a long while
Yes he was previously in the Senate, however, and is now a congressman
We have a US senator on our DMC...you would likely know that if you actually read instead of talked all the time.
“When lives are at stake there is no time to waste”
These are the ones listed are being priority:
Regeneron, Lenzilumab, Aviptadil, Favipiravir and Molnupiravir.
Very interesting!!
They never unblind until all patients have gone fully through protocol, which is 28 days. All clinical studies are the same in that regard.
Yes thanks. Sorry you feel you wasted your time
It is just old is all. Not emotionally charged, but too many are posting old or already known information as if it is new and in some way negative. No offense meant
WE KNEW THIS A MONTH AGO!!!!! Stop already. Not new news.
THIS IS A MONTH AGO!!!!! Stop already. Not new news.
Thanks for verifying!
You stated “CEO just on Swiss National news 7:30”.... so if it was actually August then you’re post is old and misleading
Post a link
This is your first post in a new account...don’t start this nonsense
What CEO??
I smell a sneaky jump upward coming today
The IDMC is typically comprised of 3–5 individuals with extensive clinical experience both in the disease under study, in the management of large complex clinical trials that represent different expertise and points of view (e.g. patient advocate).
We have 7....thoughts?
I think the DMC addition of four new names is something we should be discussing more. In my opinion they’ve done this in anticipation of great data, and want multiple individuals to validate which would strengthen their case for immediate authorization of EUA. Thoughts?
Interesting day. Looking for this to bust upwards and for us to get enrollment completion notification from company within the next day or so
A pr announcement for enrollment completion would be nice
Or for $2+ in a few weeks? Smarter money will prevail
Also less expensive to produce, manufacture, distribute, etc...not a small detail or something to overlook.
If we get final patient enrolled this week, as some have predicted, then it would be 28 days from that date we are able to unblind all data, correct? So we are realistically looking at no sooner than around the holidays for that answer? FDA likely not to act until then, however I think in the next 2 weeks we see EUA happen and the first leg up
Let’s see if this can run through the day. It would be great to see this finally catch fire and be valued higher, as it SHOULD be
In my humble opinion, we lose less in a scenario where we get EUA, a vaccine gets FDA approval, and then we follow that and also get FDA approval as a compliment to an entire treatment portfolio available to the public. In my mind that means we win twice and also own the entire therapeutic portion of treatment for those who get COVID. Thoughts?
Interesting action on bid/ask...looks like we might open green, and the opposite of what we have seen with the Swiss thus far today
Nah, that’s been mentioned before, just FYI
Bid/ask already slowly creeping up...this is not like the dump a little over a week ago
Nah, we will end in the .40’s, maybe .44 or so is my guess. They are close to enrollment completion and data read outs. Silly to sell at this point
Anything new? I watched up through the first 5 slides